MedTrace Logo

Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma

NCT03253536 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-08-18

No results posted yet for this study

Summary

Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.

Conditions

  • Hepatocellular Cancer
  • Quality of Life
  • Stereotactic Body Radiation Therapy
  • Observational

Interventions

OTHER

observational

none (observational study)

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Falk Roeder, MD · Department of Radiation Oncology, University Hospital, LMU Munich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-10
Primary Completion
2022-07-10
Completion
2027-07-10

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253536 on ClinicalTrials.gov